Two UK-based specialty companies, Sinclair Pharma and IS Pharma, are in "advanced discussions regarding a possible merger" to create Sinclair IS Pharma. The combined company could boost market access for specialty products across Europe, the companies claim.
Two UK-based specialty companies, Sinclair Pharma and IS Pharma, are in "advanced discussions regarding a possible merger" to create Sinclair IS Pharma. The combined company could boost market access for specialty products across Europe, the companies claim.
The proposed transaction is an all-share offer by Sinclair for the entire share capital of IS Pharma. The companies believe...
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
